← Home
📢 Press Releases
| Date | Press release |
|---|---|
| 2026-02-23 17:00:00 | Astellas And Vir Biotechnology Announce Global Strategic Collaboration To Advance Psma-targeting Pro-xten® Dual-masked T-cell Engager Vir-5500 For The Treatment Of Prostate Cancer - astellas and vir biotechnology to co-develop and co-commercialize vir-5500 through a sharing of expenses and revenues - - astellas to lead commercialization of vir-5500 in the u.s. with vir biotechnology retaining option to co-promote, and astellas will obtain exclusive rights to commercialize vir-5500 ex-u.s. - - vir biotechnology will receive $335m in upfront and near-term milestone payments, will split u.s. profit/loss equally with astellas (50/50), and is eligible to receive up to an additional $1.37b in development, regulatory and sales milestones, along with tiered, double-digit royalties on ex-u.s. net sales - - vir biotechnology to host conference call today at 2:30 p.m. pt / 5:30 p.m. |
| 2026-01-06 18:30:00 | Astellas To Present At 44th Annual J.p. Morgan Healthcare Conference Tokyo, jan. 6, 2026 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, ’astellas’) today announced it will present at the 44th annual j.p. morgan healthcare conference, taking place january 12-15, 2026, in san francisco, calif. |
| 2025-12-11 07:30:00 | Autobahn Labs Forms Strategic Partnership With Astellas To Accelerate Academic Discoveries Into New Medicines Palo alto, calif., dec. 11, 2025 (globe newswire) -- autobahn labs (“autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development programs, announced today a strategic partnership with global life sciences company astellas pharma inc. (“astellas”). |
| 2025-12-10 18:30:00 | Astellas To Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio At 2026 Asco Gi Cancers Symposium - data reflect new insights and precision oncology advancements in portfolio and pipeline - - cohort results from phase 2 ilustro study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (gej) cancer featured in late-breaking oral presentation - tokyo , dec. 10, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, ’astellas’) today announced it will present data on potential treatments for pancreatic and gastric/gastroesophageal junction (g/gej) cancer at the 2026 american society of clinical oncology (asco) gastrointestinal (gi) cancers symposium taking place january 8-10, 2026 in san francisco, california. highlights include a late-breaking oral presentation of cohort results from the phase 2 ilustro study of first-line zolbetuximab in combination with chemotherapy and immunotherapy in claudin 18.2-positive, her2-negative, locally advanced or metastatic g/gej cancer, as well as new phase 1 data from asp3082 (setidegrasib), an investigational kras g12d targeted protein degrader, in pancreatic cancer. |
| 2025-12-05 08:00:00 | Astellas To Present New Data On Xospata™ (gilteritinib) Across The Flt3m+ Aml Disease Continuum At Ash 2025 Annual Meeting - presentations include pooled post-hoc analysis of the phase 3 admiral and commodore data on post-transplant gilteritinib resumption in relapsed or refractory flt3m+ aml - - findings from the phase 3 morpho trial in the post-transplant maintenance setting and phase 1/2 viceroy trial in newly diagnosed disease highlight how treatment timing, sequencing and combination approaches may influence outcomes - tokyo , dec. 5, 2025 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, ’astellas’) today announced that new data evaluating xospata™ (gilteritinib) across fms-like tyrosine kinase 3 mutation-positive (flt3m+) acute myeloid leukemia (aml), including in relapsed or refractory (r/r), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming american society of hematology (ash) annual meeting taking place from 6-9 december 2025 in orlando, fla. through ongoing research with gilteritinib, astellas is advancing the science of flt3m+ aml and generating new evidence across the disease stages, to help improve long-term outcomes for people diagnosed with flt3m+ aml. |
| 2025-10-23 08:00:00 |
|
| 2025-10-22 08:00:00 |
|
| 2025-10-14 20:00:00 |
|
| 2025-10-08 19:30:00 |
|
| 2025-09-29 02:00:00 |
|
| 2025-07-17 00:00:00 |
|
| 2025-06-13 01:10:00 |
|
| 2025-05-29 20:15:00 |
|
| 2025-05-28 10:00:00 |
|
| 2025-05-21 11:00:00 |
|
📰 Browse additional press releases for Astellas Pharma!
Sign up for free or log in👥 Free eBook for new users: "The Checklist Value Investor — A Smarter Way to Pick Stocks"